Amorphous solid dispersion formulations

By forming an amorphous solid dispersion with a cap-dependent endonuclease inhibitor and a pharmaceutically acceptable polymer, the challenge of oral administration caused by the low water solubility of the compound was overcome, achieving a highly effective treatment for influenza virus infection.

CN116963739BActive Publication Date: 2026-06-09TAIGEN BIOTECHNOLOGY CO LTD +1
View PDF 4 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
TAIGEN BIOTECHNOLOGY CO LTD
Filing Date
2021-12-30
Publication Date
2026-06-09

AI Technical Summary

Technical Problem

In the prior art, cap-dependent endonuclease inhibitor compounds are difficult to develop into effective oral formulations due to their low water solubility, which limits their application in the treatment of influenza virus infection.

Method used

Amorphous solid dispersion technology is used to mix cap-dependent nuclease inhibitors or their pharmaceutically acceptable salts with pharmaceutically acceptable polymers such as PVP, PVP-VA, and Soluplus to form amorphous solid dispersions, thereby improving their solubility and bioavailability.

Benefits of technology

This invention achieves high solubility and bioavailability of cap-dependent endonuclease inhibitors, making them suitable for oral administration and effective treatment or prevention of influenza virus infection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004280376040000061
    Figure BDA0004280376040000061
  • Figure BDA0004280376040000064
    Figure BDA0004280376040000064
  • Figure BDA0004280376040000073
    Figure BDA0004280376040000073
Patent Text Reader

Abstract

Provided is an amorphous solid dispersion of a cap-dependent endonuclease inhibitor or a pharmaceutically acceptable salt thereof for oral administration, wherein the cap-dependent endonuclease inhibitor or the pharmaceutically acceptable salt thereof is dispersed in a matrix formed by a pharmaceutically acceptable polymer, and further disclosed are a preparation method of the amorphous solid dispersion and its use for treating viral infection, and a pharmaceutical composition containing the amorphous solid dispersion.
Need to check novelty before this filing date? Find Prior Art